Tokyo, Japan—Kyowa Hakko Bio announced in a press release that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Rayong Province, Thailand. It is scheduled to open in the summer of 2022.

Kyowa has already established an industrial-scale HMO production system, the press release notes, and the actual application of the system will play a major role in the company’s growth strategy. Kyowa plans to supply HMOs to other companies, as well as to use it for its own product development.

Kyowa is making the move with expectations that global demand for HMOs will increase. The press release says that the expansion will help Kyowa consolidate its position as a global specialty fermentation manufacturer.

Related: AIDP Acquires Tech, IP of Olygose SAS KeHE Switches CA Facility to Sustainable Power Source #NaturallyInformed: Driving Education in the Microbiome Space